PT - JOURNAL ARTICLE AU - Eunkyung Park TI - A New Era of Clinical Dopamine Transporter Imaging Using <sup>123</sup>I-FP-CIT AID - 10.2967/jnmt.112.111617 DP - 2012 Dec 01 TA - Journal of Nuclear Medicine Technology PG - 222--228 VI - 40 IP - 4 4099 - http://tech.snmjournals.org/content/40/4/222.short 4100 - http://tech.snmjournals.org/content/40/4/222.full SO - J. Nucl. Med. Technol.2012 Dec 01; 40 AB - 123I-labeled 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane (123I-FP-CIT) was approved for clinical use in 2011 by the Food and Drug Administration. 123I-FP-CIT is a radioligand for brain dopamine transporter (DAT) imaging that is useful for the differential diagnosis of Parkinson disease (PD) and other diseases that mimic PD. The sensitivity and specificity of 123I-FP-CIT SPECT for PD diagnosis are more than 90% and equivalent to those of other DAT SPECT methods. In the near future, the clinical indications of DAT imaging are expected to be broadened; for example, including treatment response assessment, disease progression monitoring, and early diagnosis of premotor PD in each individual patient.